Endologix (ELGX) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Partners Cuts Price Target on Endologix (ELGX) Following In-Line 3Q
November 2, 2016 7:34 AM EDTLeerink Partners maintained a Market Perform rating on Endologix (NASDAQ: ELGX), and cut the price target to $11.00 (from $13.00), following the company's 3Q earnings report. Revenues of $52.1MM was above the Street's $51.9MM as OUS sales came in slightly above expectations. EPS reported a loss of ($0.11), beating... More
